Sheppard Mullin advised DNA Holdings Venture, Inc., as the strategic advisor and investor to Predictive Oncology Inc.'s (Nasdaq: POAI) major private placement transactions totaling $344.4 million. DNA Holdings Venture will serve as a consultant to Predictive Oncology's new digital asset treasury strategy centered on Aethir (ATH) tokens and provide Predictive Oncology the ability to manage, acquire and monetize its token holdings, while aligning with its financial strategy. The transactions, composed of both cash and crypto private investment in public equity transactions (PIPEs), will fund Predictive Oncology's initiatives in AI-driven drug discovery and development.
The Sheppard Mullin deal team was led by partner Richard Friedman, special counsel Sean Reid, partner Stephen Cohen and associates Michael Blane and Emily Mastoloni, with invaluable assistance from special counsel Daniel Clausen and partner Dmitriy Chelnitsky.
Read the press release here.